Market Overview

UPDATE: Piper Jaffray Cuts PT to $8 on Rigel Pharmaceuticals Following Disappointing Phase II Results

Related RIGL
Mid-Afternoon Market Update: Crude Oil Down Over 2.5%; American Express Shares Gain On Earnings Beat
18 Biggest Mid-Day Losers For Thursday

Piper Jaffray reiterated its Overweight rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and increased its price target from $14 to $8.

Piper Jaffray commented, "We are maintaining our Overweight rating but cutting our price target to $8 from $14 following disappointing results from the OSKIRA-4 Phase II trial. In particular, fostamatinib's inability to achieve non-inferiority to Abbott's Humira could have negative commercial implications. As a result, we have reduced our fostamatinib revenue estimates."

Rigel Pharmaceuticals closed at $5.90 on Wednesday.

Latest Ratings for RIGL

Sep 2016JefferiesMaintainsBuy
Aug 2016BMO CapitalMaintainsOutperform
Aug 2016BMO CapitalInitiates Coverage onOutperform

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (RIGL)

View Comments and Join the Discussion!